In 2025, Alzheimer Europe:
- Provided a voice to people affected by dementia and
- involved 18 people with dementia from 12 European countries in its European Working Group of People with Dementia (EWGPWD) and organised two in-person and four online meetings
- involved 17 carers of people with dementia from 15 European countries in its European Dementia Carers Working Group (EDCWG) and organised two in-person and three online meetings
- co-developed a report on the ethical, social and practical implications of the use of technology by and for people with dementia
- dedicated the first plenary of its Annual Conference to a session entitled “Dementia as a European and national policy and research priority – as seen by people with dementia and their carers”, which was planned, organised, moderated and presented by members of the EWGPWD and EDCWG
- included testimonials from people with dementia and carers in its 2025 Yearbook on transport and access to cultural life, recreation, leisure and sport
- included articles written by people with dementia and carers in its monthly e-mail newsletters and Dementia in Europe magazine
- participated with an EWGPWD delegation in the European Day of Persons with Disabilities
- involved members of both groups in publications, meetings as well as through Public Involvement activities in its European dementia and brain health research projects.
- Made dementia a European priority and
- contributed to European Commission consultations by submitting position papers and by co-developing policy statements with other European disability and health NGOs
- participated as an active member in the meetings of the Patients’ and Consumers’ Working Party of the European Medicines Agency
- closely followed the discussions on the introduction and authorisation of anti-amyloid treatments in Europe and produced a statement on the re-examination of the marketing authorisation application for donanemab, which it shared with the European Medicines Agency
- updated its 2019 report on the numbers of people affected by dementia in the European Union, publishing “The Prevalence of Dementia in Europe 2025” report
- organised one in-person and two online meetings of the European Group of Governmental Experts on Dementia, bringing together representatives from 25 countries, as well as the European Commission, Organisation for Economic Co-operation and Development (OECD) and the World Health Organization (WHO)
- worked with members of the European Alzheimer’s Alliance (EAA), which consists of 89 MEPs from 22 Member States of the European Union, to make dementia a European priority, including organising two European Parliament lunch debates and inviting EAA contributions to the Dementia in Europe magazine
- dedicated its 2025 Yearbook to transport and access to cultural life, recreation, leisure and sport and carried out a survey in which 33 members participated
- monitored EU and national policy developments of interest to people with dementia and their carers and identified 41 European and 16 national policy news to include in its newsletters.
- Changed perceptions and combatted stigma and
- launched the call for its fourth Anti-stigma Award, inviting European artists active in the field of painting or photography and addressing the stigma attached to dementia whilst encouraging a positive image of dementia and people living with dementia, in collaboration with the Alzheimer Europe Foundation, C2N Diagnostics, Lilly and Roche
- organised an Anti-Stigma Award ceremony and dinner, hosted by Nina Carberry MEP (Ireland) on 2 December and announced Alex Kornhuber as the winner, for “Keepsake Chronicles”, an Irish-born collaboration between the photographer, a poet (Cathy Fowley), and a nurse (Kate Irving), with second place going to Desideria Care e.V. for their open-air photo exhibition “Seeing Dementia in a New Light”, and third place to Bálint Szajki, a photographer from Hungary, for his deeply intimate photo essay, titled “In Sickness and in Health”
- participated in an online question and answer session with touchNEUROLOGY discussing how stigma affects people living with dementia and strategies to raise awareness of this topic.
- Raised awareness of brain health and prevention and
- identified five phase II trials, four phase III trials and one non-drug trial to include in its Clinical Trials Watch service
- participated in a growing number of European research projects focused on brain health, risk reduction and prevention, biomarkers and novel therapies
- continued to collaborate with the European Task Force on Brain Health, co-authoring a publication that identified opportunities and challenges for the implementation of Brain Health Services from a range of different perspectives, including patient and societal perspectives
- contributed to a panel discussion on dementia prevention and risk reduction broadcast by the Luxembourg radio station RTL
- contributed to scientific publications on psychosocial interventions, biomarkers, multimodal lifestyle interventions, brain health services, physical activity, anti-amyloid therapies, palliative care, prediction models, genetic determinants, technology, informed consent and risk disclosure, Public Involvement, participation in dementia research, and precision medicine
- published a special supplement to its October edition of Dementia in Europe magazine on the topic of Brain Health, examining dementia risk reduction and prevention from a European perspective, covering primary, secondary and tertiary prevention and underlining the importance of action across the life course and across all stages of dementia.
- Strengthened the European dementia movement and
- organised two in-person Public Affairs meetings and seven online Alzheimer’s Association Academy meetings with the participation of members from 34 European countries
- involved the AE Board in the monitoring of the association’s activities and finances in relation to the agreed-upon Work Plan and budget and organised two online and three in-person meetings
- organised two Annual General Meetings
- in Brussels (Belgium) on 4 June with 29 of its 36 full members present or represented, where it welcomed five new full members and where the members approved the 2024 Annual and Financial Reports
- online on 24 November 2025, with 35 out of 41 full members present or represented where the members unanimously adopted the 2026 Work Plan and Budget and new Strategic Plan of Alzheimer Europe (2026-2030)
- continued its collaboration with the INTERDEM network of European researchers involved in psychosocial research, the European Alzheimer’s Disease Consortium and the European Academy of Neurology
- collaborated as a full member with the European Patients’ Forum and the European Disability Forum and was also accepted as a member of the European Public Health Alliance
- partnered with other organisations in the European Care Alliance, coordinated by COFACE – Families Europe to contribute to EU discussions and policy initiatives in the field of informal and professional care.
- Supported dementia research and
- involved the EWGPWD and the EDCWG, as well as its online Public Involvement Pool in the Public Involvement activities of European research projects
- contributed to a research paper entitled “Informed Consent in dementia research: how Public Involvement can contribute to addressing “old” and “new” challenges”
- contributed to the communication and dissemination of research results via its established communication tools: newsletter, website and social media and covered 485 news stories in its 11 monthly e-mail newsletters which were sent to over 10,000 subscribers
- organised its 35th Annual Conference “Connecting Science and Communities: The future of dementia care” in Bologna (Italy) from 6 to 8 October with a record number of more than 1,500 delegates from 48 countries
- collaborated with the Alzheimer Europe Foundation which provided bursaries for people with dementia and early-stage researchers to participate in the conference and which funded the meeting costs, as well as the travel and accommodation costs of the member of the EWGPWD and EDCWG attending the conference.
- Carried out the following project-related activities
- continued its involvement in a number of EU-funded projects by representing the views of people with dementia and their carers in the research consortium, by contributing to the ethical discussions and by supporting the communication and dissemination activities towards a non-scientific audience with the following projects
- ADIS (Early Diagnosis of Alzheimer's Disease by Immune Profiling of Cytotoxic Lymphocytes and Recording of Sleep Disturbances)
- AD-RIDDLE (Real-world implementation, deployment and validation of early detection tools and lifestyle enhancement)
- AI-MIND (Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment)
- AI4Hope (Artificial intelligence-based health, optimism, purpose and endurance in palliative care for dementia)
- eBRAIN-Health (Actionable Multilevel Health Data)
- EPND (European Platform for Neurodegenerative Diseases)
- LETHE (A personalized prediction and intervention model for early detection and reduction of risk factors causing dementia, based on explainable AI and distributed Machine Learning)
- Multi-MeMo (Shorter- and longer-term mechanisms of multimodal interventions to prevent dementia)
- Pattern-Cog (Personalized aging pattern for early risk detection and prevention of cognitive impairment and dementia in cognitively healthy individuals)
- PREDICTOM (Prediction of Alzheimer’s disease using an AI driven screening platform)
- PROMINENT (Precision medicine platform in neurodegenerative disease).
- Started its collaboration with
- DORIAN GRAY (Devising a personalised risk stratification and holistic management for prevention of cognitive impairment in patients with different cardiovascular phenotypes)
- FluiDx-AD (A novel test trio to detect peptide biomarkers in saliva and blood for enhanced diagnosis and management of Alzheimer's Disease)
- PREDICT-FTD (Accelerating the Validation of Predictive Liquid Biomarkers for Frontotemporal Dementia Diagnosis and Subclassification).
- Supported the following EU projects
- EPAD (European Prevention of Alzheimer’s Dementia)
- HOMEDEM (CoDesigning a home with dementia)
- PANEUCARE (Multidirectional knowledge transfer of dementia research and care between European and international regions)
- REBALANCE (Mechanisms of focused ultrasound mediated brain cleaning coupled with enhanced mechanosensation)
- REMOTE-AD (Remote Digital Assessment and Monitoring for Early Alzheimer's Disease)
- TEF-Health (Testing and Experimentation Facility for Health AI and Robotics).
- continued its involvement in a number of EU-funded projects by representing the views of people with dementia and their carers in the research consortium, by contributing to the ethical discussions and by supporting the communication and dissemination activities towards a non-scientific audience with the following projects
- carried out a number of activities thanks to the support of its corporate sponsors and other partners
- organised two European Parliament lunch debates on “Preparing for new Alzheimer’s treatments in Europe” and on “The future of dementia research in Europe”, with support from Sirpa Pietikäinen MEP (Finland), Romana Jerković MEP (Croatia), Hilde Vautmans MEP (Belgium) and Tilly Metz MEP (Luxembourg)
- published three editions of the Dementia in Europe magazine with interviews and contributions of EU and national policy makers, as well as three special supplements, one for each edition of the magazine, dedicated to the 2024 Annual Conference, the AI-Mind project and to Brain Health
- ended the year with 22 phase II trials, 12 phase III clinical trials and three non-drug trials recruiting participants in Europe included in the Clinical Trials Watch on the organisation’s website
- continued a project funded by Gates Ventures exploring the attitudes and barriers of the general public towards participation in dementia and brain health research
- organised regular company round table meetings and consultations with its sponsors
- participated in meetings of the Patient think-tank of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and collaborated with PAVE, Project Alzheimer’s Value in Europe.